Research compounds
SLU-PP-332
ERR agonist, exercise mimetic
SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors, publicised in 2023 as an "exercise in a pill" candidate. It is a preclinical compound with no human data and is not approved anywhere.
Also known as: SLU PP 332, SLUPP332, ERR agonist
- Status
- SLU-PP-332 is a research compound and not approved by the FDA for human use.
- Evidence
- Preclinical. Evidence comes from animal or lab studies; effects in people are not established.
- Half-life
- Short; requires twice-daily dosing in rodent studies.
- How it's taken
- Injection in the preclinical research setting
- Mechanism
- Metabolic (non-incretin)
- Pathways
- Mitochondrial
How SLU-PP-332 works
The estrogen-related receptors ERR-alpha, beta and gamma are orphan nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism, and are among the transcriptional programmes activated by endurance exercise. SLU-PP-332 activates all three, and in mice increased mitochondrial function, running endurance and resistance to diet-induced obesity without changing food intake.
What research has looked at
- The mouse data are real: increased endurance capacity and mitochondrial gene expression, with effects on heart failure models reported subsequently.
- ERR is a legitimate node in the exercise-response transcriptional network, downstream of PGC-1alpha.
- It works without appetite suppression, distinguishing it mechanistically from incretin-based weight approaches.
Evidence level: Preclinical. Evidence comes from animal or lab studies; effects in people are not established. These are areas studied or reported, not promised effects.
Reported side effects and risks
- There are no human studies of any kind — not even Phase 1. Everything known about it comes from mice and cell culture. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Its pharmacokinetics require frequent injection in rodents; it is not an orally convenient compound as popularly described.
- Chronic pan-activation of a family of nuclear receptors with broad transcriptional roles has entirely uncharacterised long-term consequences, including in tissues not intended as targets.
- Media coverage as "exercise in a pill" substantially outran the evidence, which is preclinical.
- It would be prohibited under the WADA Prohibited List as a metabolic modulator.
Sources
- PubMed research on SLU-PP-332 ERR agonist exercise mimetic mouse · NIH · National Library of Medicine
- DrugBank record for SLU-PP-332 · DrugBank
- Active clinical trials for SLU-PP-332 · U.S. National Library of Medicine
Track SLU-PP-332 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
SLU-PP-332 FAQ
What is SLU-PP-332?
SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors, publicised in 2023 as an "exercise in a pill" candidate. It is a preclinical compound with no human data and is not approved anywhere.
How does SLU-PP-332 work?
The estrogen-related receptors ERR-alpha, beta and gamma are orphan nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism, and are among the transcriptional programmes activated by endurance exercise. SLU-PP-332 activates all three, and in mice increased mitochondrial function, running endurance and resistance to diet-induced obesity without changing food intake.
Is SLU-PP-332 FDA approved?
No. SLU-PP-332 is a research compound and not approved by the FDA for human use. Evidence level: preclinical. Evidence comes from animal or lab studies; effects in people are not established.
What is the half-life of SLU-PP-332?
Reported half-life: Short; requires twice-daily dosing in rodent studies.
How is SLU-PP-332 taken?
Injection in the preclinical research setting.
What side effects have been reported with SLU-PP-332?
Reported in the sources: There are no human studies of any kind — not even Phase 1. Everything known about it comes from mice and cell culture. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Its pharmacokinetics require frequent injection in rodents; it is not an orally convenient compound as popularly described; Chronic pan-activation of a family of nuclear receptors with broad transcriptional roles has entirely uncharacterised long-term consequences, including in tissues not intended as targets; Media coverage as "exercise in a pill" substantially outran the evidence, which is preclinical; It would be prohibited under the WADA Prohibited List as a metabolic modulator.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.